Reviewer's report
Title:Improvement of long-term outcomes in pancreatic cancer within the
gemcitabine era: A collaborative retrospective multicenter clinical review of 1,082
patients
Version: 2Date:28 June 2013
Reviewer: david goldstein
Reviewer's report:
I think the authors have tried hard to respond to all of my issues and indeed
those of the other reviewers.
I still feel quite strongly that lumping locally advanced stage IVa and stage 1-111
as a single surgical group is inappropriate and can only mask any benefit form
adjuvant chemotherapy.
I believe despite the small numbers that the only valid analysis is one where the
outcomes for stage 1-111 with and without chemotherapy are compared
separately and stage IVa with and without chemotherapy.
I think there is a real chance of showing some benefit form adjuvant
chemotherapy when stage IVa are excluded and their data will be more
comparable to non japanese surgical and adjuvant data when this analysis is
done
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Reviewer's report
Title:Improvement of long-term outcomes in pancreatic cancer within the
gemcitabine era: A collaborative retrospective multicenter clinical review of 1,082
patients
Version: 2Date:28 June 2013
Reviewer: david goldstein
Reviewer's report:
I think the authors have tried hard to respond to all of my issues and indeed
those of the other reviewers.
I still feel quite strongly that lumping locally advanced stage IVa and stage 1-111
as a single surgical group is inappropriate and can only mask any benefit form
adjuvant chemotherapy.
I believe despite the small numbers that the only valid analysis is one where the
outcomes for stage 1-111 with and without chemotherapy are compared
separately and stage IVa with and without chemotherapy.
I think there is a real chance of showing some benefit form adjuvant
chemotherapy when stage IVa are excluded and their data will be more
comparable to non japanese surgical and adjuvant data when this analysis is
done
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Please review this paper.
user
Reviewer's report
Title:Improvement of long-term outcomes in pancreatic cancer within the
gemcitabine era: A collaborative retrospective multicenter clinical review of 1,082
patients
Version: 2Date:28 June 2013
Reviewer: david goldstein
Reviewer's report:
I think the authors have tried hard to respond to all of my issues and indeed
those of the other reviewers.
I still feel quite strongly that lumping locally advanced stage IVa and stage 1-111
as a single surgical group is inappropriate and can only mask any benefit form
adjuvant chemotherapy.
I believe despite the small numbers that the only valid analysis is one where the
outcomes for stage 1-111 with and without chemotherapy are compared
separately and stage IVa with and without chemotherapy.
I think there is a real chance of showing some benefit form adjuvant
chemotherapy when stage IVa are excluded and their data will be more
comparable to non japanese surgical and adjuvant data when this analysis is
done
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
assistant